In addition to inhibiting RIPK1 and RIPK3, inhibition of the TLR4 pathway by TAK-242 or TLR4 deficiency was found to significantly reduce circulating ammonia levels, which was validated in clinically relevant models of hyperammonemia due to cirrhosis or UCD. Here, RIPK3 is linked to urea cycle disorder.